Compare JPMorgan Chase & Co (JPM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Viatris Inc — how do they compare? JPMorgan Chase & Co trades at $345.22 (market cap $900.78B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: JPMorgan Chase & Co is far larger — about 45.5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| JPM | VTRS | |
|---|---|---|
Market Cap | $900.78B | $19.79B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $17.39 |
52-Week Low | $282.84 | $8.74 |
Dividend Yield | 1.77% | 2.83% |
Enterprise Value | — | $32.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $345.23, up 1.21% on the day, with a bullish technical outlook and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside a consensus price target of $372.73, signal positive momentum. Revenue growth is robust, rising to $181.85B in 2025, though net income dipped slightly to $57.05B. The stock benefits from institutional accumulation and media focus on CEO Jamie Dimon's economic insights.
The outlook for JPM remains favorable, driven by earnings resilience and sector leadership, but risks include geopolitical tensions, cybersecurity threats, and volatile cash flows. With a moderate buy rating from analysts and a reasonable P/E of 14.52, the stock offers value, though investors should weigh macroeconomic headwinds against its solid fundamentals.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
